采用FACT-H N评价核黄素磷酸钠对喉癌放疗患者生存质量的影响

摘要

目的：采用FACT-H&N量表评价核黄素磷酸钠对喉癌放疗患者生存质量的影响。方法选取我院肿瘤科首次接受放射治疗的喉癌患者72例，随机分为观察组和对照组，每组36例。观察组自放疗开始每日应用核黄素磷酸钠20 mg静脉输液，直至放疗结束；对照组单纯放疗，不使用核黄素磷酸钠。观察两组患者放疗后放射性口咽黏膜炎的发生率和摄食量，分别于放疗前( D1)和放疗后( D2)采用FACT-H&N量表作为评测工具，评价放疗前后两组患者生存质量。结果观察组放射性口咽黏膜炎的发生率低于对照组，两组比较差异有统计学意义(P<0．05)；观察组患者摄食量与对照组比较差异有统计学意义(P<0．05)；生存质量方面，观察组在身体状况、社会家庭、情感及功能共性模块评分均高于对照组，在头颈部模块的附加条目领域得分低于对照组，两组比较差异有统计学意义(P<0．05)。结论核黄素磷酸钠可降低放射性口咽黏膜炎发生率，改善喉癌放疗患者摄食量下降，提高喉癌放疗患者生存质量，值得临床推广。%Objective Using FACT-H&N scale to evaluate the effect of riboflavin sodium phosphate on the quality of life of patients with laryngeal carcinoma who received radiotherapy. Methods Seventy-two patients with la-ryngeal carcinoma who underwent radiotherapy for the first time were randomly divided into observation group and con-trol group. Patients in observation group (n=36) accepted daily application of riboflavin sodium phosphate 20 mg in-travenous infusion throughout the course of radiotherapy. Patients in control group only received radiotherapy. The oc-currence of oropharyngeal mucositis and food intake after radiotherapy were assessed by FACT-HN scale to evaluate the quality of life of patients before (D1) and after (D2) radiotherapy. Results The incidence of oral mucositis in obser-vation group was lower than that of control group,there was significant difference (P<0. 05);There was significant difference in the food intake status between the two groups (P<0. 05);For the quality of life,the scores of physical condition,social and family,the general module emotional and functional in patients of observation group were higher than those of control group (P<0. 05),and the scores of the head and neck module additional entry field of observa-tion group were lower than those than that of control group (P<0. 05),the difference was significant. Conclusion Riboflavin sodium phosphate can reduce the incidence of radioactive oral mucositis,improve the decrease of food intake in laryngeal carcinoma patients who underwent radiotherapy and improve the quality of life,it is worthy of clinical pro-motion.